Phase IB Trial of LDE225 and Weekly Paclitaxel in Recurrent Platinum Resistant Ovarian Cancer

Trial Profile

Phase IB Trial of LDE225 and Weekly Paclitaxel in Recurrent Platinum Resistant Ovarian Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Sonidegib (Primary) ; Paclitaxel
  • Indications Ovarian cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
    • 06 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 28 Sep 2016 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top